57f2cc66-9163-4e07-93f8-d5a2158e7125
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- TGF_BETA_SIGNALING+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- G2M_CHECKPOINT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MITOTIC_SPINDLE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- UV_RESPONSE_DN+0.400
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.600
- ADIPOGENESIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- FATTY_ACID_METABOLISM-0.400
- GLYCOLYSIS-0.400
- MTORC1_SIGNALING-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- MYC_TARGETS_V2-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- XENOBIOTIC_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613802 | — | D | 0.874 |
| 2 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.863 |
| 3 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.849 |
| 4 | TCGA-BH-A0B5-01A-11R-A12P-07 | — | A | 0.845 |
| 5 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.844 |
| 6 | s0122308 | — | — | 0.841 |
| 7 | TCGA-85-8287-01A-11R-2296-07 | — | cohortSQ1 | 0.829 |
| 8 | TCGA-BH-A1FE-01A-11R-A13Q-07 | — | A | 0.825 |
| 9 | SRR4296078 | — | cohortSQ1 | 0.824 |
| 10 | TCGA-56-8625-01A-11R-2403-07 | — | cohortSQ1 | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |